Abstract 1437P
Background
Tissue biopsy (TIB) is the gold standard for biomarker testing in mNSCLC patients. Although TIB is common, it is associated with potential invasive procedure-related complications. Liquid biopsies are used when tissue is unavailable or insufficient for testing. Studies suggest that TFLB has comparable diagnostic accuracy to TIB for detecting genetic alterations in mNSCLC patients. Liquid biopsies are increasingly used to genotype a tumor in a less invasive manner. This study compared TIB-related complications and healthcare costs with TRB vs. TFLB in mNSCLC patients.
Methods
US administrative claims were assessed retrospectively for patients diagnosed with mNSCLC between July 2016 to June 2021 to identify adult Medicare Advantage or commercially insured patients with ≥2 biopsy claims, and whose first biopsy was tissue-based. The second biopsy defined the cohorts: TRB or TFLB. To control for possible confounding factors, study cohorts were matched 1:1 using propensity-scores (PSM).
Results
The study comprised 470 patients post-PSM, each group had 235 patients. TFLB had a lower TIB-related complication rate and associated healthcare costs compared with TRB (Table). Furthermore, mean number of complication-related healthcare visits were lower for TFLB than TRB group; outpatient visits (0.51 v 1.12, p=0.002), inpatient stays (0.45 v 0.67, p<0.001) and inpatient days (3.49 v 6.60, p=0.002). Table: 1437P
Comparison of outcomes between study cohorts
TFLB (N = 235) | TRB (N = 235) | |
TIB-related complications (%)* | 65.1 | 84.7 |
Pneumothorax* | 17.5 | 46.0 |
Prolonged air leak >5 days* | 1.3 | 11.9 |
Hemorrhage | 14.0 | 18.3 |
Infection* | 23.0 | 31.9 |
Thrombotic complications | 13.2 | 8.5 |
Cardiovascular complications | 38.7 | 42.1 |
Death | 0.4 | 2.6 |
Mean [SD] TB complication-related healthcare costs - US$ | ||
Medical costs* | 8,494 [15,706] | 19,741 [30,641] |
Office visits* | 20 [71] | 51 [219] |
Outpatient visits | 251 [1,672] | 336 [1,562] |
Emergency room visits | 119 [590] | 85 [358] |
Inpatient stays* | 8,076 [15,338] | 18,918 [30,012] |
Other medical costs | 29 [148] | 352 [3622] |
∗P-value <0.05
Conclusions
The analysis suggests that TFLB, compared with traditional TRB, is a method that carries less economic burden and fewer TIB-related complications to detect actionable genetic mutations during mNSCLC diagnostic work-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Optum.
Funding
AstraZeneca.
Disclosure
N.M. Engel-Nitz: Financial Interests, Personal, Stocks/Shares: United Health Group; Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca. A. Shah, J. Apple: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. S. Aslam: Financial Interests, Personal, Stocks/Shares: United Health Group; Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca. L. Le: Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca; Financial Interests, Personal, Stocks/Shares: United Health Group. M. Terpenning: Financial Interests, Personal, Financially compensated role: Optum; Financial Interests, Personal, Stocks/Shares: Johnson & Johnson, Stryker.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20